ACADIA PHARMACEUTICALS INC.
Cash Flow Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $33.4M | $16.6M | $45.8M | $-65.2M | $1.1M | $-43.0M | $-41.7M | $-27.2M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $226.0K | $242.0K | $272.0K | $359.0K | $402.0K | $426.0K | $489.0K | $506.0K |
| Amortization | $2.3M | $5.3M | $1.4M | $1.4M | $1.4M | $0 | $0 | $0 |
| Stock-Based Compensation | $15.7M | $14.8M | $18.0M | $18.5M | $15.2M | $14.7M | $14.4M | $18.3M |
| Net Cash from Operating Activities | $25.0M | $29.1M | $85.4M | $-59.0M | $8.2M | $-17.9M | $-23.9M | $-727.0K |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | $0 | $0 |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-56.2M | $-14.0M | $-347.0K | $34.1M | $-194.3M | $192.5M | $-17.7M | $15.4M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $3.6M | $1.0M | $5.4M | $12.8M | $5.5M | $1.5M | $1.6M | $287.0K |
| Net Change in Cash | $-27.6M | $16.1M | $90.5M | $-12.1M | $-180.6M | $176.0M | $-40.0M | $15.0M |
| Free Cash Flow | — | — | — | — | — | — | $-23.9M | $-727.0K |